Cracking The Code: Understanding Analyst Reviews For BioNTech

Loading...
Loading...

In the preceding three months, 7 analysts have released ratings for BioNTech BNTX, presenting a wide array of perspectives from bullish to bearish.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 5 1 1 0 0
Last 30D 1 0 0 0 0
1M Ago 3 1 1 0 0
2M Ago 1 0 0 0 0
3M Ago 0 0 0 0 0

Analysts have set 12-month price targets for BioNTech, revealing an average target of $145.43, a high estimate of $171.00, and a low estimate of $100.00. This upward trend is evident, with the current average reflecting a 5.38% increase from the previous average price target of $138.00.

Analyzing Analyst Ratings: A Detailed Breakdown

The analysis of recent analyst actions sheds light on the perception of BioNTech by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Bill Maughan Canaccord Genuity Maintains Buy $171.00 -
Chris Shibutani Goldman Sachs Lowers Neutral $100.00 $113.00
Bill Maughan Canaccord Genuity Maintains Buy $171.00 -
Etzer Darout BMO Capital Announces Outperform $127.00 -
Bill Maughan Canaccord Genuity Maintains Buy $171.00 -
Bill Maughan Canaccord Genuity Raises Buy $171.00 $168.00
Robert Burns HC Wainwright & Co. Lowers Buy $107.00 $133.00

Key Insights:

Loading...
Loading...
  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to BioNTech. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of BioNTech compared to the broader market.
  • Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of BioNTech's stock. This comparison reveals trends in analysts' expectations over time.

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of BioNTech's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on BioNTech analyst ratings.

About BioNTech

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. COVID-19 vaccine Comirnaty is its first commercialized product.

BioNTech: Financial Performance Dissected

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Decline in Revenue: Over the 3 months period, BioNTech faced challenges, resulting in a decline of approximately -74.13% in revenue growth as of 30 September, 2023. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: BioNTech's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 17.94%, the company may face hurdles in effective cost management.

Return on Equity (ROE): BioNTech's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.81%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): BioNTech's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.72%, the company may face hurdles in achieving optimal financial performance.

Debt Management: BioNTech's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.

How Are Analyst Ratings Determined?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Loading...
Loading...
Market News and Data brought to you by Benzinga APIs
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...